Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Carolin Dodt - , Medizinische Klinik Winterthur (Autor:in)
  • Mathias W Pletz - , Universitätsklinikum Jena (Autor:in)
  • Martin Kolditz - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität Dresden, BioRegionen Deutschland e.V. (Autor:in)

Abstract

The key priority in patients with chronic lung diseases is currently immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); all vaccines approved for this showed high effectiveness against severe infections. For patients with chronic pulmonary diseases the recommendations by the Standing Committee on Vaccination include not only the standard vaccinations in adulthood but also the so-called indication vaccinations. These include vaccinations against pneumococci and influenza. Advances include the recent development of new pneumococcal conjugate vaccines containing additional serotypes and the recommendation of a more effective high-dose vaccine against influenza for persons over 60 years old. With the next scheduled booster vaccination against tetanus and diphtheria a combination vaccine with pertussis antigen should be used. For patients with chronic lung disease the herpes zoster vaccine is recommended over the age of 50 years.

Details

OriginalspracheDeutsch
Seiten (von - bis)327-338
Seitenumfang12
FachzeitschriftDer Pneumologe
Jahrgang18
Ausgabenummer5
PublikationsstatusVeröffentlicht - 2021
Peer-Review-StatusJa

Externe IDs

PubMedCentral PMC8274260
ORCID /0000-0001-6022-6827/work/127318524
Scopus 85110017224

Schlagworte

Ziele für nachhaltige Entwicklung